Abstract
Cisplatin-based combination chemotherapy yields cure rates >90% in patients with nonseminomatous germ-cell tumors that are classified by the International Germ Cell Cancer Collaborative Group (IGCCCG) as good risk. Unfortunately, patients with IGCCCG intermediate- and poor-risk tumors have cure rates of only 81% and 48%, respectively. These problematic subgroups of patients have been targeted for a variety of clinical approaches during the years, including cisplatin dose intensification, upfront ifosfamide therapy, and high-dose chemotherapy with stem-cell rescue. To date, …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
